Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Bisacodyl

AEMPS

Stimulant laxatives

ATC code: A06AB02

Brand names: Dulcolax

Updated · Methodology

Indications

B

Chronic constipation

Second line

Per 2023 and 2014, stimulant laxatives are second-line for chronic constipation in adults after baseline measures (adequate hydration, fiber, physical activity) and osmotic laxatives (PEG, lactulose). Bisacodyl 5–10 mg at bedtime. Efficacy confirmed by meta-analyses. Continuous use beyond 1–2 weeks is linked to hypokalemia and 'colonic conditioning' – the clinical significance of melanosis coli and dependence is now debated in guidelines, but long-term self-medication is not recommended.

Sources

  1. Gastroenterology: American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation (2023)
  2. American Journal of Gastroenterology: American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation (2023)
  3. American Journal of Gastroenterology: American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation (2014)
  4. Clinical Gastroenterology and Hepatology: Oral Bisacodyl Is Effective and Well-Tolerated in Patients With Chronic Constipation (2011)
  5. The Lancet Gastroenterology & Hepatology: Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis (2019)

ICD-10: K59.0 · ICD-11: ME05.0

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

F

Weight loss

Not recommended

Bisacodyl and other laxatives for weight loss are unsafe – they cause electrolyte disturbance, dehydration, acid-base imbalance, and iatrogenic 'lazy bowel' with long-term use. In patients with eating disorders, laxative abuse marks serious pathology requiring psychiatric and psychotherapeutic support. Apparent weight loss is water – not fat.

Sources

  1. Drugs: Laxative abuse: epidemiology, diagnosis and management. (2010)
  2. Am J Public Health: Diet Pill and Laxative Use for Weight Control and Subsequent Incident Eating Disorder in US Young Women: 2001-2016. (2020)
  3. Rapid Commun Mass Spectrom: Establishment of high-performance liquid chromatography-photodiode array method for 43 weight loss agents and effect of basic environment on bisacodyl degradation. (2024)
How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

Stimulates sensory nerve endings in the colonic mucosa, increasing peristalsis and lumenal water and electrolyte secretion. Activated by bacterial deacetylase in the colon. Effect 6–12 hours after oral, 15–60 minutes after rectal administration. In children and patients with denuded mucosa, may cause cramping pain and electrolyte disturbance.

Safety

Contraindications

  • Intestinal obstruction, perforation
  • Acute appendicitis, peritonitis
  • Severe dehydration
  • Acute inflammatory bowel disease
  • Age under 6 (oral 5 mg form)
  • Hypersensitivity

Serious adverse effects

  • Electrolyte disturbance (hypokalemia) with long-term use
  • Dehydration in elderly
  • Melanosis coli (benign, reversible)

Common adverse effects

  • Abdominal cramping
  • Diarrhea, increased stool frequency
  • Nausea

Pregnancy: can you take Bisacodyl?

AEMPS summary of product characteristics (section 4.6): there are not enough data on bisacodyl use in pregnant women, and its possible effects on the fetus are unknown. Because a small amount of bisacodyl is absorbed, it should not be used during pregnancy unless the doctor judges that the benefits outweigh the possible risks.

Breastfeeding: can you take Bisacodyl?

Minimal systemic absorption. Compatible with breastfeeding.

Calculate RIDFull profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Timing and administration

Take at bedtime — effect at 6–12 hours in the morning. Swallow the tablet whole — the enteric coating prevents gastric irritation. Avoid milk, antacids, or PPIs within 1 hour — the coating dissolves in the stomach and causes nausea and cramping. Continuous use beyond 7–10 days without medical advice is not recommended. Constipation lasting over 2 weeks warrants evaluation.
Label mentions8 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

  • antiácidosclass named in the label
    «La leche y los fármacos antiácidos y antiulcerosos (inhibidores de la bomba de hidrogeniones, antihistamínicos H 2 ) pueden aumentar la absorción del bisacodilo, por lo que se aconseja distanciar la…»

    AEMPS, section 4.5 · Open on CIMA

  • antiarrítmicosclass named in the label
    «La hipopotasemia (resultante del abuso de laxantes a largo plazo) potencia la acción de los glucósidos cardíacos (digoxina) e interacciona con los fármacos antiarrítmicos (por ej. quinidina).»

    AEMPS, section 4.5 · Open on CIMA

  • antihistamínicosclass named in the label
    «La leche y los fármacos antiácidos y antiulcerosos (inhibidores de la bomba de hidrogeniones, antihistamínicos H 2 ) pueden aumentar la absorción del bisacodilo, por lo que se aconseja distanciar la…»

    AEMPS, section 4.5 · Open on CIMA

  • corticosteroidesclass named in the label
    «La administración concomitante de bisacodilo con otros medicamentos inductores de hipopotasemia (por ej. diuréticos tiacídicos, adrenocorticosteroides y raíz de regaliz ) puede favorecer el…»

    AEMPS, section 4.5 · Open on CIMA

  • digitálicosclass named in the label
    «La hipopotasemia (resultante del abuso de laxantes a largo plazo) potencia la acción de los glucósidos cardíacos (digoxina) e interacciona con los fármacos antiarrítmicos (por ej. quinidina).»

    AEMPS, section 4.5 · Open on CIMA

  • Digoxin
    «La hipopotasemia (resultante del abuso de laxantes a largo plazo) potencia la acción de los glucósidos cardíacos (digoxina) e interacciona con los fármacos antiarrítmicos (por ej. quinidina).»

    AEMPS, section 4.5 · Open on CIMA

  • diuréticosclass named in the label
    «La administración concomitante de bisacodilo con otros medicamentos inductores de hipopotasemia (por ej. diuréticos tiacídicos, adrenocorticosteroides y raíz de regaliz ) puede favorecer el…»

    AEMPS, section 4.5 · Open on CIMA

  • Quinidine
    «La hipopotasemia (resultante del abuso de laxantes a largo plazo) potencia la acción de los glucósidos cardíacos (digoxina) e interacciona con los fármacos antiarrítmicos (por ej. quinidina).»

    AEMPS, section 4.5 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Bisacodyl used for?

Bisacodyl is evaluated for the following indications with varying evidence strength: Chronic constipation (evidence tier B), Weight loss (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Bisacodyl?

Common side effects of Bisacodyl (≥ 1 in 100): Abdominal cramping, Diarrhea, increased stool frequency, Nausea. See the Safety section for uncommon and serious reactions.

Is Bisacodyl safe during pregnancy?

AEMPS summary of product characteristics (section 4.6): there are not enough data on bisacodyl use in pregnant women, and its possible effects on the fetus are unknown. Because a small amount of bisacodyl is absorbed, it should not be used during pregnancy unless the doctor judges that the benefits outweigh the possible risks.

Is Bisacodyl compatible with breastfeeding?

Minimal systemic absorption. Compatible with breastfeeding.

Who should not take Bisacodyl?

Bisacodyl is contraindicated in: Intestinal obstruction, perforation; Acute appendicitis, peritonitis; Severe dehydration; Acute inflammatory bowel disease; Age under 6 (oral 5 mg form). Full list in the Safety section.

Official sources

Direct links to regulator labels. Open in a new tab.

Other drugs in this group

Glycerol, Inulin (chicory/agave/Jerusalem artichoke prebiotic), Psyllium (Plantago ovata, ispaghula husk), Sodium lauryl sulfoacetate, Sodium picosulfate